The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk is moving forward with plans to develop oral obesity drugs through a new partnership, which comes as longtime CEO Lars Fruergaard Jørgensen prepares to step down. The drugmaker launched a ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. In the meantime, a search for Jørgensen’s successor is ongoing. Novo Nordisk says the leadership transition is “made in ...

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...